Every 8-K that Bio-Techne Corp (TECH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TECH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TECH filings page.
Bio-Techne Corporation reported fourth-quarter fiscal 2026 net sales of $321.2 million, up 1% year over year, with organic revenue up 3%. GAAP diluted EPS improved to $0.35 from a loss of $(0.11), while adjusted EPS was $0.52 versus $0.53. GAAP operating income was $74.3 million compared with a prior-year loss, and GAAP operating margin rose to 23.1%, helped by the absence of last year’s impairment. Adjusted operating income increased to $103.4 million and adjusted operating margin to 32.2%.
For full-year fiscal 2026, net sales were flat at $1.22 billion. GAAP diluted EPS increased to $1.16 from $0.46, and adjusted EPS edged up to $1.93 from $1.92. Full-year GAAP operating income rose to $251.9 million with a 20.7% operating margin, while adjusted operating income reached $386.1 million. The Protein Sciences segment grew revenue 1% to $874.6 million with a 41.1% operating margin; Diagnostics and Spatial Biology revenue declined 3% to $336.4 million, but its operating margin improved to 11.2%.
The company highlighted a previously announced agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, implying enterprise value of about $11.3 billion. Bio-Techne also declared a quarterly cash dividend of $0.08 per share, payable September 4, 2026, to shareholders of record on August 24, 2026.
Bio-Techne Corporation has agreed to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash merger. Each outstanding share of Bio-Techne common stock (other than excluded and restricted shares) will be converted into the right to receive $73.00 in cash, subject to tax withholding.
Vested stock options will be cashed out for the in-the-money value, while unvested options, RSUs, PSUs and restricted stock convert into cash-based awards that retain their vesting schedules. Closing requires shareholder approval and antitrust and investment screening clearances, with an outside date of March 25, 2027, extendable to September 25, 2027. The company may owe Merck a $230.455 million termination fee in certain scenarios, while Merck may owe Bio-Techne $576.14 million in others. Named executives receive substantial cash retention bonuses payable at closing or if the merger agreement terminates under specified conditions.
Bio-Techne Corporation agreed to be acquired by Merck KGaA, Darmstadt, Germany for US$73 per share in cash, implying a total enterprise value of about US$11.3 billion and a 36% premium to Bio-Techne’s one-month volume weighted average price.
The deal, unanimously approved by Bio-Techne’s board and Merck’s relevant corporate bodies, is expected to close by late 2026 or early 2027, subject to shareholder and regulatory approvals and other customary conditions. Merck plans to fund the purchase with existing cash and new debt while maintaining an investment-grade rating.
Management expects the transaction to be immediately accretive to EBITDA pre margin for Merck’s Life Science business and to become EPS pre accretive by year three after closing, supported by about EUR 140 million of cost synergies targeted by year three. Bio-Techne generated net sales of more than US$1.2 billion in fiscal year 2025 and brings strong positions in multi-omics, spatial biology, cell and gene therapy, and precision diagnostics.
Bio-Techne Corporation reported mixed third quarter fiscal 2026 results. Net sales were $311.4 million, down 2% year over year, with organic revenue also declining 2% as prior-year GMP fast-track orders and timing of large Commercial Supply shipments weighed on growth.
GAAP earnings improved sharply, with diluted EPS rising to $0.32 from $0.14, driven by a 95% increase in GAAP operating income to $75.5 million and a higher 24.2% operating margin helped by profitability initiatives and the Exosome Diagnostics divestiture. On a non-GAAP basis, adjusted EPS slipped to $0.53 from $0.56 and adjusted operating margin eased to 34.2% from 34.9%.
The Protein Sciences segment posted revenue of $226.2 million, down 1%, with organic revenue down 4%, while Diagnostics and Spatial Biology revenue declined 4% to $85.6 million but delivered 3% organic growth and margin expansion. The company ended the period with $209.8 million in cash and equivalents and reduced long-term debt to $200 million. The Board declared a quarterly cash dividend of $0.08 per share, payable May 29, 2026 to shareholders of record on May 18, 2026.
Bio-Techne Corporation announced a leadership change in its Diagnostics and Spatial Biology Segment, with Dr. Matt McManus transitioning from his role and Steve Crouse, currently Senior Vice President of the Analytical Solutions Division, becoming segment president effective March 1, 2026.
Crouse’s executive employment agreement provides a $505,000 annual base salary and a target annual cash bonus equal to 75% of base pay, plus eligibility for standard employee benefits. He will receive a one-time equity grant of stock options and restricted stock units valued at approximately $170,000 in total at target, and ongoing annual equity awards with grant date values of $300,000 in stock options, $300,000 in time-vested restricted stock units, and $600,000 in performance-based restricted stock units at target. If terminated without cause, after a change in control, or for good reason, he is entitled to one year of base salary, a prorated bonus, and one year of health coverage, subject to a release of claims. The Board approved the termination of McManus’s employment without cause, making him eligible for severance under his agreement. The company highlights that it generated over $1.2 billion in net sales in fiscal 2025 and employs about 3,100 people worldwide.
Bio-Techne Corporation reported that it issued a press release on February 4, 2026 describing its results of operations for the quarter and six months ended December 31, 2025 and its financial condition as of that date. The company also issued a separate press release on the same day announcing a cash dividend, which is attached as another exhibit.
Bio‑Techne Corporation filed an 8‑K reporting that it issued a press release describing results of operations for the quarter ended September 30, 2025 and its financial condition as of that date. The company also announced via a separate press release that its Board declared a cash dividend.
Shareholders held the Annual Meeting with a quorum of 140,827,559 shares, representing approximately 90.45% of outstanding shares. Shareholders set the number of directors at nine (For 140,278,598; Against 314,005; Abstain 234,956), and elected all nine nominees by a majority standard. The advisory vote on executive compensation passed (For 100,792,824; Against 39,025,321; Abstain 1,009,414). Shareholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026 (For 137,578,559; Against 3,055,503; Abstain 193,497).